• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Prenetics' IM8 Partners with Superpower to Personalize the Future of Supplementation

    3/24/26 11:00:00 AM ET
    $PRE
    Blank Checks
    Finance
    Get the next $PRE alert in real time by email
    • IM8 90-Day Subscribers Unlock SuperPower Blood Testing for $49 — A 75% Saving on the Standard $199 Price.
    • IM8 and Superpower create the first closed-loop system in consumer health – connecting clinical-grade supplementation with 100+ biomarker blood testing.
    • IM8's Daily Ultimate Essentials will be available in the Superpower supplement marketplace and featured, where biomarker data supports it, as one of Superpower's recommended foundational daily supplements in members' personalized health protocols.



    NEW YORK, March 24, 2026 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ:PRE) ("Prenetics" or the "Company"), a leading consumer health sciences company and parent of the IM8 premium health and longevity brand, today announced a strategic partnership with Superpower, the preventive health platform backed by over $40 million in venture funding. The first-of-its-kind partnership connects clinical-grade supplementation with comprehensive blood diagnostics, enabling an optimized testing loop to provide consumers with measurable proof behind supplement efficacy.

    IM8 and Superpower are teaming up to address a fundamental gap within the wellness industry: most people who take supplements have no way to measure whether they're working; meanwhile, most blood testing platforms surface hundreds of data points, but leave consumers to navigate a fragmented, low-quality supplement market on their own. Neither side has been able to close the gap alone – until now.

    Under the partnership, IM8 — co-founded by David Beckham — will integrate Superpower's annual blood testing membership into the IM8 customer journey at exclusive pricing, while Superpower will integrate IM8's Daily Ultimate Essentials into its personalized health protocols as a featured foundational nutritional ritual, available to all members on its supplement marketplace at a preferred rate. The partnership reflects a broader shift in how consumers approach their health; from reactive treatment to proactive optimization, powered by personal data.

    "I co-founded IM8 with David Beckham to fix the quality problem in supplements — clinical-grade formulations, full transparency, no shortcuts," said Danny Yeung, CEO of Prenetics and IM8. "But formulation was only half the equation. The other half was measurement. With Superpower, an IM8 customer can now test 100+ biomarkers, take our products for 90 days, retest, and see measurable results. That's not a marketing claim. That's proof. No other supplement brand on the market can offer that."

    [1] IM8 subscribers on the 90-day Daily Ultimate Essentials plan will be able to redeem a Superpower membership for $49 per year, which translates to a 75% saving on Superpower's standard $199 annual price. Monthly IM8 subscribers will gain access to the Superpower membership for $99 per year, a 50% saving. Both tiers include Superpower's complete offering: its comprehensive initial 100+ biomarker test, an AI health layer grounded in each individual's real data – not generic advice, and 24/7 access to its concierge care team. Members can upload past labs, share their health history, and get personalized insights to help them achieve their health goals. Testing is available at over 2,000 Quest Diagnostics locations nationwide, or via at-home blood draw for an additional fee. Baseline biomarker retests and additional specialty diagnostic tests are also available to members at preferred pricing.

    [2] "We built Superpower to move healthcare from reactive to proactive – but proactive only works when testing leads to action, and action leads back to testing," said Max Marchione, Co-Founder and CEO of Superpower. "That feedback loop has never existed in consumer health until now. IM8 gives our members a supplement protocol we can stand behind with full confidence — clinical-grade formulations built for the same standard of evidence our platform is built on. This is what the future of health looks like: data in, protocol out, results measured."

    IM8 ships to 31 countries and counts tennis world number one Aryna Sabalenka and Formula 1 driver Ollie Bearman among its brand ambassadors. Superpower's investors include NBA champion Giannis Antetokounmpo and the Winklevoss twins, and the platform has built the infrastructure to make preventive blood testing as routine and affordable as a gym membership.

    The integrated offering is available now. To learn more, IM8 customers can access Superpower membership pricing at im8health.com, and Superpower members can explore IM8's product range at superpower.com.

    About Prenetics

    Prenetics (NASDAQ:PRE) is a leading health sciences company dedicated to advancing human health and longevity. The Company's flagship consumer brand, IM8, co-founded with David Beckham and championed by World No. 1 tennis player Aryna Sabalenka, is redefining the premium daily nutrition category through science-backed formulations and global brand partnerships. Since its launch, IM8 has become one of the fastest-growing brands in consumer health, achieving an impressive milestone of surpassing $100 million in annualized recurring revenue within just 11 months of operations, and is now sold in more than 31 countries worldwide.

    About IM8

    IM8 is the pinnacle of premium core nutrition, born from a collaboration between David Beckham as a co-founding partner, and an elite team of scientists spanning medical professionals, academia and space science. Combining cutting-edge science with nature's most potent ingredients, IM8 delivers a holistic, science-backed approach to health, empowering you to live your most vibrant life. IM8's flagship product, Daily Ultimate Essentials is an all-in-one powder supplement engineered to replace 16 different supplements in a delicious drink and is NSF Certified for Sport, non-GMO, vegan, free from common allergens, and contains no artificial flavors, colors or sweeteners. IM8 is a subsidiary of Prenetics (NASDAQ:PRE), a leading global health sciences company dedicated to advancing consumer health. To learn more about IM8, please visit www.IM8health.com.

    About Superpower

    Superpower is a new kind of health membership - built on comprehensive lab work, not guesswork. For $199 per year, members get annual blood testing across 100+ biomarkers, an AI health layer grounded in their real data, personalized health protocols, and 24/7 concierge care. Founded by Max Marchione and Jacob Peters, Superpower has raised over $40 million in funding with its Series A led by Forerunner Ventures. Superpower is accessible at over 2,000 Quest Diagnostics locations across the US, with at-home blood draws also available. To learn more about Superpower, please visit superpower.com.

    Investor Relations Contact:

    [email protected]

    [email protected]

    Angela Cheung

    Investor Relations / Corporate Finance

    [email protected]



    Primary Logo

    Get the next $PRE alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PRE

    DatePrice TargetRatingAnalyst
    3/16/2026$29.00Buy
    Lake Street
    2/11/2026$36.00Buy
    Roth Capital
    1/18/2023$7.00Overweight
    Cantor Fitzgerald
    7/12/2022Buy
    Citigroup
    More analyst ratings

    $PRE
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Prenetics' IM8 Partners with Superpower to Personalize the Future of Supplementation

    IM8 90-Day Subscribers Unlock SuperPower Blood Testing for $49 — A 75% Saving on the Standard $199 Price.IM8 and Superpower create the first closed-loop system in consumer health – connecting clinical-grade supplementation with 100+ biomarker blood testing.IM8's Daily Ultimate Essentials will be available in the Superpower supplement marketplace and featured, where biomarker data supports it, as one of Superpower's recommended foundational daily supplements in members' personalized health protocols. NEW YORK, March 24, 2026 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ:PRE) ("Prenetics" or the "Company"), a leading consumer health sciences company and parent of the IM8 premium heal

    3/24/26 11:00:00 AM ET
    $PRE
    Blank Checks
    Finance

    Prenetics to Participate in the 38th Annual ROTH Conference

    NEW YORK, March 18, 2026 (GLOBE NEWSWIRE) -- Prenetics Global Limited (PRE) ("Prenetics" or the "Company"), a leading consumer health sciences company and parent of the IM8 premium health and longevity brand, today announced the Company will participate in the 38th Annual ROTH Conference being held Sunday, March 22nd to Tuesday, March 24th at the Ritz-Carlton in Laguna Niguel, CA. Prenetics CEO Danny Yeung and President of Americas David Vanderveen will be available for one-on-one meetings throughout the conference. Management will also participate in a fireside chat at 8:30 a.m. PT and a Consumer Influencer panel discussion at 12:00 p.m. PT on Monday, March 23rd — both available via webc

    3/18/26 8:30:00 AM ET
    $PRE
    Blank Checks
    Finance

    Prenetics Authorizes $40 Million Share Repurchase Program

    Management and Board Have Collectively Committed Up to $42.75 Million to Prenetics Stock Backed by $164 Million in Total Adjusted Liquidity, Zero Debt IM8 Targeting $180M to $200M in 2026 Full Year Revenue, and a Clear Path to Adjusted EBITDA Profitability by Q4 2027 NEW YORK, March 06, 2026 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ:PRE) ("Prenetics" or the "Company"), a leading consumer health sciences company and parent of the IM8 premium health and longevity brand, today announced that its Board of Directors (the "Board") has authorized a share repurchase program of up to $40,000,000 over a 12-month period. Management Voted With Its Own Capital First During the week of Feb

    3/6/26 8:00:00 AM ET
    $PRE
    Blank Checks
    Finance

    $PRE
    SEC Filings

    View All

    SEC Form 6-K filed by Prenetics Global Limited

    6-K - Prenetics Global Ltd (0001876431) (Filer)

    3/6/26 8:07:42 AM ET
    $PRE
    Blank Checks
    Finance

    SEC Form 6-K filed by Prenetics Global Limited

    6-K - Prenetics Global Ltd (0001876431) (Filer)

    3/3/26 8:47:27 AM ET
    $PRE
    Blank Checks
    Finance

    SEC Form 6-K filed by Prenetics Global Limited

    6-K - Prenetics Global Ltd (0001876431) (Filer)

    2/18/26 9:28:49 AM ET
    $PRE
    Blank Checks
    Finance

    $PRE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Lake Street initiated coverage on Prenetics Group Ltd. with a new price target

    Lake Street initiated coverage of Prenetics Group Ltd. with a rating of Buy and set a new price target of $29.00

    3/16/26 8:45:09 AM ET
    $PRE
    Blank Checks
    Finance

    Roth Capital initiated coverage on Prenetics Group Ltd. with a new price target

    Roth Capital initiated coverage of Prenetics Group Ltd. with a rating of Buy and set a new price target of $36.00

    2/11/26 7:52:37 AM ET
    $PRE
    Blank Checks
    Finance

    Cantor Fitzgerald initiated coverage on Prenetics Group Ltd. with a new price target

    Cantor Fitzgerald initiated coverage of Prenetics Group Ltd. with a rating of Overweight and set a new price target of $7.00

    1/18/23 7:56:45 AM ET
    $PRE
    Blank Checks
    Finance

    $PRE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Cheng Yin Pan

    3 - Prenetics Global Ltd (0001876431) (Issuer)

    3/24/26 10:30:07 AM ET
    $PRE
    Blank Checks
    Finance

    SEC Form 3 filed by new insider Lo Hoi Chun

    3 - Prenetics Global Ltd (0001876431) (Issuer)

    3/18/26 11:17:48 AM ET
    $PRE
    Blank Checks
    Finance

    SEC Form 3 filed by Prenetics Global Limited

    3 - Prenetics Global Ltd (0001876431) (Issuer)

    3/18/26 11:02:27 AM ET
    $PRE
    Blank Checks
    Finance

    $PRE
    Leadership Updates

    Live Leadership Updates

    View All

    Formula 1 Phenom Ollie Bearman Joins Prenetics' IM8 Health as Global Ambassador and Shareholder

    Ollie Bearman becomes the latest elite athlete to invest in NASDAQ:PRE, underscoring a deep belief in the brand's mission and products.IM8, co-founded by David Beckham, continues to attract top-tier athletes who prioritize scientifically validated and trusted nutritional support.IM8 has become one of the fastest-growing supplement brands globally, achieving an extraordinary US$100 million in Annual Recurring Revenue in just 11 months from launch.Bearman's rapid rise – including a historic points-scoring Ferrari debut at just 18—cements his reputation as one of motorsport's brightest young talents. NEW YORK, Feb. 13, 2026 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ:PRE), a leading

    2/13/26 8:00:00 AM ET
    $PRE
    Blank Checks
    Finance

    Prenetics Becomes First Healthcare Company to Execute Aggressive Bitcoin Treasury Strategy, Secures $20M in BTC, Appoints Former OKEx COO to Board

    -  Prenetics adopts proven corporate Bitcoin strategy inspired by MicroStrategy's ~$40B Bitcoin holdings and Metaplanet's meteoric treasury transformation -  Following strategic divestiture, Prenetics leverages strengthened $117M balance sheet to execute comprehensive Bitcoin strategy with board-approved majority allocation, institutional financing partnerships, and alpha-generating initiatives. CHARLOTTE, N.C., June 18, 2025 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ:PRE), a leading health sciences company, today announced it has become the first healthcare company to establish a Bitcoin treasury, completing a $20 million Bitcoin purchase of 187.42 BTC at an averag

    6/18/25 8:45:00 AM ET
    $PRE
    Blank Checks
    Finance

    Prenetics Welcomes Kathyrn M. Henry and David Vanderveen to Board of Directors

    LOS ANGELES, July 01, 2024 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ:PRE) ("Prenetics" or the "Company"), a leading health sciences company, welcomes Kathryn M. Henry and David Vanderveen as independent directors to the Company's Board of Directors. "We are excited to welcome Kathryn and David to Prenetics' Board of Directors at this pivotal juncture," said Danny Yeung, CEO of Prenetics. "Their unparalleled expertise in consumer and health sectors, combined with their proven leadership in driving global expansion and operational excellence, will significantly enhance shareholder value as we expand into consumer health and wellness." "I am thrilled to join Prenetics at such a p

    7/1/24 8:30:00 AM ET
    $PRE
    Blank Checks
    Finance

    $PRE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Prenetics Global Limited

    SC 13G/A - Prenetics Global Ltd (0001876431) (Subject)

    11/14/24 12:30:15 PM ET
    $PRE
    Blank Checks
    Finance

    SEC Form SC 13G/A filed by Prenetics Global Limited (Amendment)

    SC 13G/A - Prenetics Global Ltd (0001876431) (Subject)

    2/5/24 6:05:14 AM ET
    $PRE
    Blank Checks
    Finance

    SEC Form SC 13G/A filed by Prenetics Global Limited (Amendment)

    SC 13G/A - Prenetics Global Ltd (0001876431) (Subject)

    11/27/23 6:05:43 AM ET
    $PRE
    Blank Checks
    Finance

    $PRE
    Financials

    Live finance-specific insights

    View All

    Prenetics Reports Record Q4 and FY 2025 Results: IM8 Achieves $120M ARR¹ in 12 Months, Revenue Surges 480% YoY

    Total Revenue Increased 480% to $92.4 million for Full Year 2025, Q4 Revenue reached $36.6 millionIM8 Reaches $10 Million in Monthly Revenue in December 2025, Achieving $120M ARR MilestoneStrategic Transformation Completed with Divestitures and Focus on IM8 Total Adjusted Liquidity2 of Approximately $171 Million Following Sale of Insighta Stake to Tencent, with Zero DebtCompany to Host Earnings Call on February 18, 2026, at 10:00 a.m. ET and latest investor deck can be found at https://ir.prenetics.com NEW YORK, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ:PRE) ("Prenetics" or the "Company"), a leading consumer health sciences company and parent of the IM8 premium he

    2/18/26 9:11:26 AM ET
    $PRE
    Blank Checks
    Finance

    Prenetics to Report Q4 and Full Year 2025 Financial Results on Feb 18, 2026 and Host Earnings Conference Call

    NEW YORK, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ:PRE) ("Prenetics" or the "Company"), a leading health sciences company and parent of the IM8 premium health and longevity brand, today announced it will release financial results for the fourth quarter and full year 2025 ended December 31, 2025 before market open on Wednesday, February 18, 2026. The Company will also hold its earnings conference call the same day at 10:00 a.m. Eastern Time to discuss its financial results in further detail. The call will conclude with a Q&A session with analysts. Date:Wednesday, February 18, 2026Time:10:00 a.m. Eastern TimeDial-in:1-877-425-9470International Dial-in:1-201-389-0878

    2/11/26 8:00:00 AM ET
    $PRE
    Blank Checks
    Finance

    Prenetics Reports Record Third Quarter 2025 Results; IM8 on Track for $120M ARR¹ by December 2025, Fastest Supplement Brand Growth in Industry History

    Total Revenue Surges 568% YoY to $23.6 million; IM8 Monthly Revenue Hits Record US$9 million in October; Bitcoin Treasury Reaches 387 BTC (~$40M); IM8 Projects $180 - $200M FY 2026 Revenue, $25M Monthly Revenue or $300M ARR by Year End 2026 IM8 Delivers 60% Gross Margin, 3.9 Months Payback Period, Demonstrating Strong Unit Economics Company to Host Earnings Call Today at 8:30am ET, Releases Inaugural Quarterly Shareholder Letter CHARLOTTE, N.C., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ:PRE) ("Prenetics" or the "Company"), a leading health sciences company and parent of the IM8 premium health and longevity brand, today announced third quarter 2025 financial

    11/10/25 7:24:27 AM ET
    $EXOD
    $PRE
    Finance: Consumer Services
    Finance
    Blank Checks